Please try another search
For the nine months ended 30 September 2017, C R Bard Inc revenues increased 6% to $2.91B. Net income applicable to common stockholders increased 11% to $409.8M. Revenues reflect Vascular segment increase of 9% to $823.4M, Oncology segment increase of 5% to $792.5M, United States segment increase of 4% to $1.98B, Europe segment increase of 1% to $332.5M. Net income benefited from Restructuring Charges/Provisions decrease of 79% to $5.6M (expense).
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 989.8 | 979.7 | 938.8 | 967.1 |
Gross Profit | 610.6 | 618.4 | 584.6 | 619 |
Operating Income | 130.3 | 184.4 | 214.3 | 216.5 |
Net Income | 94.1 | 139.7 | 178.1 | 159.6 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 5353.8 | 5244.6 | 5306.1 | |
Total Liabilities | 3499.3 | 3572.8 | 3631 | |
Total Equity | 1854.5 | 1671.8 | 1675.1 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 0 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 317 | 140.6 | 546.6 | |
Cash From Investing Activities | -65 | -28.3 | -423.9 | |
Cash From Financing Activities | -240.2 | -150.8 | -149.8 | |
Net Change in Cash | 23.5 | -36.7 | -45.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review